Screener
Kura Oncology KURA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | March 31, 2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.0001 par value; 200,000 shares authorized; 88,763 and 87,855 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
| Additional paid-in capital | 1,355,675 | 1,347,190 |
| Accumulated other comprehensive income (loss) | (380) | 1,024 |
| Accumulated deficit | (1,247,421) | (1,174,088) |
| Total stockholders’ equity | 107,883 | 174,135 |
| Total liabilities and stockholders’ equity | $652,551 | $738,363 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's total equity?
- Kura Oncology (KURA) reported total equity of $107.88M in Q1 2026.
- How has Kura Oncology's total equity changed year-over-year?
- Kura Oncology's total equity decreased by 70.4% year-over-year, from $364.41M to $107.88M.
- What is the long-term trend for Kura Oncology's total equity?
- Over 5 years (2020 to 2025), Kura Oncology's total equity has grown at a -22.2% compound annual growth rate (CAGR), from $610.91M to $174.14M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Kura Oncology's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude